Market closedNon-fractional
Altimmune/ALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Altimmune
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Ticker
ALT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Gaithersburg, United States
Employees
59
Website
altimmune.com
Altimmune Metrics
BasicAdvanced
$474M
Market cap
-
P/E ratio
-$1.59
EPS
0.10
Beta
-
Dividend rate
Price and volume
Market cap
$474M
Beta
0.1
Financial strength
Current ratio
16.546
Quick ratio
16.289
Long term debt to equity
0.025
Total debt to equity
0.319
Interest coverage (TTM)
-2,604.26%
Management effectiveness
Return on assets (TTM)
-29.48%
Return on equity (TTM)
-54.46%
Valuation
Price to revenue (TTM)
953.263
Price to book
2.74
Price to tangible book (TTM)
2.74
Price to free cash flow (TTM)
-5.371
Growth
Revenue change (TTM)
-618.99%
Earnings per share change (TTM)
-10.07%
3-year revenue growth (CAGR)
-60.81%
3-year earnings per share growth (CAGR)
-5.81%
What the Analysts think about Altimmune
Analyst Ratings
Majority rating from 8 analysts.
Altimmune Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$24M
-23.10%
Profit margin
0.00%
NaN%
Altimmune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.39
-$0.54
-$0.34
-
Expected
-$0.46
-$0.42
-$0.43
-$0.37
-$0.35
Surprise
-31.12%
-8.14%
24.55%
-7.39%
-
Altimmune News
AllArticlesVideos
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
GlobeNewsWire·2 days ago
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
Accesswire·3 weeks ago
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $474M as of July 27, 2024.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of July 27, 2024.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Altimmune stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.